The world’s first antibacterial peptide wound dressing — FDA De Novo grant

Amferia’s patented technology kills 99.99% of bacteria in the dressing — without leaching into the wound. FDA De Novo granted for human use in the U.S.

Learn more

For the first time, unleashing the power of antimicrobial peptides

Peptides can now be used in medical devices to kill bacteria. Mimicking our own immune system, it is non toxic and safe.

How it works

How this platform technology
can revolutionise treatments

Amferia’s general patent now granted in Europe, the U.S. and China

Amferia’s innovation is protected by three strong patent families. The basic patent is already in force in Europe, the U.S. and China, and pending in several other countries. Ongoing R&D continues to generate new patent applications.

Read about all our patents >

United States patent sheet

Addressing antibiotic resistance the sustainable way

Read about the global threat and Amferia's vision >

After years of research, we suddenly realised how to combine our findings. 
It was a eureka moment.

Read about the Amferia story >

Amferia Annual General Meeting (AGM) Appoints Global Healthcare Leaders Randy Schwartz and Nikolaj Sørensen to Board of Directors

The latest news from Amferia >